1Tsushima T, Hironaka S, Boku N, et al. Safety and efficacy of S- 1 monotherapy in elderly patients with advanced gastric cancer [J]. Gastric Cancer,2010,13(4) :245-250. 被引量：1
2Nishiyama M, Wada S. Docetaxel: its role in current and future treatments for advanced gastric cancer [ J]. Gastric Cancer,2009, 12(3) :132-141. 被引量：1
1Tsushima T, Hironaka S, Boku N, et al. Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer[ J]. Gastric Cancer, 2010,13(4): 245-250. 被引量：1
2Nishiyama M, Wada S. Docetaxel: its role in current and future treatments for advanced gastric cancer[ J]. Gastric Cancer, 2009, 12 ( 3 ) : 132 - 141. 被引量：1
3Van-Cutsem E, Moiseyenko V M, Tjulandin S, et al. PhasebⅢ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group [ J ]. J Clin Oncol, 2006, 24 (31 ) :4991 - 4997. 被引量：1
4Kang H, Kauh J S. Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard? [ J]. Curr Treat Options Oncol, 2011, 12(1) : 96 -106. 被引量：1
